![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ACADM |
Gene summary for ACADM |
![]() |
Gene information | Species | Human | Gene symbol | ACADM | Gene ID | 34 |
Gene name | acyl-CoA dehydrogenase medium chain | |
Gene Alias | ACAD1 | |
Cytomap | 1p31.1 | |
Gene Type | protein-coding | GO ID | GO:0000271 | UniProtAcc | A0A0S2Z366 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
34 | ACADM | LZE2T | Human | Esophagus | ESCC | 2.15e-03 | 3.15e-01 | 0.082 |
34 | ACADM | LZE4T | Human | Esophagus | ESCC | 1.52e-11 | 2.03e-01 | 0.0811 |
34 | ACADM | LZE7T | Human | Esophagus | ESCC | 1.45e-05 | 5.09e-01 | 0.0667 |
34 | ACADM | LZE8T | Human | Esophagus | ESCC | 4.40e-05 | 7.16e-02 | 0.067 |
34 | ACADM | LZE20T | Human | Esophagus | ESCC | 8.98e-09 | 2.49e-01 | 0.0662 |
34 | ACADM | LZE22D1 | Human | Esophagus | HGIN | 1.60e-02 | 2.43e-01 | 0.0595 |
34 | ACADM | LZE22T | Human | Esophagus | ESCC | 2.80e-10 | 7.61e-01 | 0.068 |
34 | ACADM | LZE24T | Human | Esophagus | ESCC | 2.38e-13 | 4.05e-01 | 0.0596 |
34 | ACADM | LZE6T | Human | Esophagus | ESCC | 5.13e-07 | 1.89e-01 | 0.0845 |
34 | ACADM | P1T-E | Human | Esophagus | ESCC | 4.20e-08 | 5.99e-01 | 0.0875 |
34 | ACADM | P2T-E | Human | Esophagus | ESCC | 7.88e-41 | 6.69e-01 | 0.1177 |
34 | ACADM | P4T-E | Human | Esophagus | ESCC | 6.05e-21 | 4.49e-01 | 0.1323 |
34 | ACADM | P5T-E | Human | Esophagus | ESCC | 5.05e-15 | 2.71e-01 | 0.1327 |
34 | ACADM | P8T-E | Human | Esophagus | ESCC | 3.60e-14 | 2.74e-01 | 0.0889 |
34 | ACADM | P9T-E | Human | Esophagus | ESCC | 1.58e-13 | 1.09e-01 | 0.1131 |
34 | ACADM | P10T-E | Human | Esophagus | ESCC | 4.84e-37 | 7.17e-01 | 0.116 |
34 | ACADM | P11T-E | Human | Esophagus | ESCC | 6.39e-16 | 4.23e-01 | 0.1426 |
34 | ACADM | P12T-E | Human | Esophagus | ESCC | 6.79e-31 | 3.29e-01 | 0.1122 |
34 | ACADM | P15T-E | Human | Esophagus | ESCC | 5.47e-18 | 3.53e-01 | 0.1149 |
34 | ACADM | P16T-E | Human | Esophagus | ESCC | 3.86e-18 | 3.41e-01 | 0.1153 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0044042 | Liver | NAFLD | glucan metabolic process | 18/1882 | 73/18723 | 2.51e-04 | 4.12e-03 | 18 |
GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
GO:0000271 | Liver | NAFLD | polysaccharide biosynthetic process | 17/1882 | 72/18723 | 6.35e-04 | 8.27e-03 | 17 |
GO:0043255 | Liver | NAFLD | regulation of carbohydrate biosynthetic process | 20/1882 | 97/18723 | 1.39e-03 | 1.56e-02 | 20 |
GO:0006112 | Liver | NAFLD | energy reserve metabolic process | 18/1882 | 84/18723 | 1.49e-03 | 1.64e-02 | 18 |
GO:0033692 | Liver | NAFLD | cellular polysaccharide biosynthetic process | 15/1882 | 65/18723 | 1.66e-03 | 1.74e-02 | 15 |
GO:00425945 | Liver | NAFLD | response to starvation | 33/1882 | 197/18723 | 2.35e-03 | 2.21e-02 | 33 |
GO:00159807 | Liver | NAFLD | energy derivation by oxidation of organic compounds | 48/1882 | 318/18723 | 2.78e-03 | 2.54e-02 | 48 |
GO:0005978 | Liver | NAFLD | glycogen biosynthetic process | 11/1882 | 44/18723 | 3.45e-03 | 2.98e-02 | 11 |
GO:0009250 | Liver | NAFLD | glucan biosynthetic process | 11/1882 | 44/18723 | 3.45e-03 | 2.98e-02 | 11 |
GO:00065754 | Liver | NAFLD | cellular modified amino acid metabolic process | 31/1882 | 188/18723 | 3.98e-03 | 3.34e-02 | 31 |
GO:00423984 | Liver | NAFLD | cellular modified amino acid biosynthetic process | 11/1882 | 46/18723 | 4.98e-03 | 3.91e-02 | 11 |
GO:0006111 | Liver | NAFLD | regulation of gluconeogenesis | 11/1882 | 48/18723 | 7.00e-03 | 4.90e-02 | 11 |
GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
GO:001598012 | Liver | Cirrhotic | energy derivation by oxidation of organic compounds | 154/4634 | 318/18723 | 3.11e-20 | 8.87e-18 | 154 |
GO:000188912 | Liver | Cirrhotic | liver development | 81/4634 | 147/18723 | 2.99e-15 | 3.35e-13 | 81 |
GO:006100812 | Liver | Cirrhotic | hepaticobiliary system development | 82/4634 | 150/18723 | 3.72e-15 | 4.09e-13 | 82 |
GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
GO:004428211 | Liver | Cirrhotic | small molecule catabolic process | 151/4634 | 376/18723 | 2.20e-11 | 1.34e-09 | 151 |
GO:001605411 | Liver | Cirrhotic | organic acid catabolic process | 104/4634 | 240/18723 | 1.91e-10 | 9.53e-09 | 104 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa002809 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0028014 | Esophagus | ESCC | Valine, leucine and isoleucine degradation | 34/4205 | 48/8465 | 2.34e-03 | 6.54e-03 | 3.35e-03 | 34 |
hsa002806 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
hsa033206 | Liver | NAFLD | PPAR signaling pathway | 25/1043 | 75/8465 | 1.61e-06 | 6.62e-05 | 5.33e-05 | 25 |
hsa012126 | Liver | NAFLD | Fatty acid metabolism | 17/1043 | 57/8465 | 3.43e-04 | 5.93e-03 | 4.78e-03 | 17 |
hsa000718 | Liver | NAFLD | Fatty acid degradation | 13/1043 | 43/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 13 |
hsa0028011 | Liver | NAFLD | Valine, leucine and isoleucine degradation | 20/1043 | 48/8465 | 3.03e-07 | 1.65e-05 | 1.33e-05 | 20 |
hsa0332011 | Liver | NAFLD | PPAR signaling pathway | 25/1043 | 75/8465 | 1.61e-06 | 6.62e-05 | 5.33e-05 | 25 |
hsa0121211 | Liver | NAFLD | Fatty acid metabolism | 17/1043 | 57/8465 | 3.43e-04 | 5.93e-03 | 4.78e-03 | 17 |
hsa0007111 | Liver | NAFLD | Fatty acid degradation | 13/1043 | 43/8465 | 1.46e-03 | 1.71e-02 | 1.38e-02 | 13 |
hsa0028021 | Liver | Cirrhotic | Valine, leucine and isoleucine degradation | 32/2530 | 48/8465 | 1.45e-07 | 2.02e-06 | 1.24e-06 | 32 |
hsa0007121 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0332021 | Liver | Cirrhotic | PPAR signaling pathway | 32/2530 | 75/8465 | 1.24e-02 | 3.92e-02 | 2.42e-02 | 32 |
hsa0028031 | Liver | Cirrhotic | Valine, leucine and isoleucine degradation | 32/2530 | 48/8465 | 1.45e-07 | 2.02e-06 | 1.24e-06 | 32 |
hsa0007131 | Liver | Cirrhotic | Fatty acid degradation | 29/2530 | 43/8465 | 3.87e-07 | 4.95e-06 | 3.05e-06 | 29 |
hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACADM | insertion | Nonsense_Mutation | novel | c.81_82insTCACGGTTGTGATCCTAGCACCTTGGGAGGCCTCGGCGGGTTG | p.Asn28SerfsTer4 | p.N28Sfs*4 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |||
ACADM | SNV | Missense_Mutation | novel | c.884T>G | p.Val295Gly | p.V295G | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ACADM | SNV | Missense_Mutation | c.561N>C | p.Leu187Phe | p.L187F | protein_coding | tolerated(0.08) | benign(0.031) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
ACADM | SNV | Missense_Mutation | c.143N>G | p.Phe48Cys | p.F48C | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ACADM | SNV | Missense_Mutation | c.274N>A | p.Pro92Thr | p.P92T | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
ACADM | SNV | Missense_Mutation | rs373715782 | c.715C>T | p.Arg239Cys | p.R239C | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
ACADM | SNV | Missense_Mutation | c.143T>G | p.Phe48Cys | p.F48C | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ACADM | SNV | Missense_Mutation | novel | c.279G>T | p.Glu93Asp | p.E93D | protein_coding | deleterious(0.01) | benign(0.371) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ACADM | SNV | Missense_Mutation | c.769G>A | p.Val257Met | p.V257M | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AG-A01N-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | SD | ||
ACADM | SNV | Missense_Mutation | c.479N>T | p.Ser160Phe | p.S160F | protein_coding | tolerated(0.13) | benign(0.053) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
34 | ACADM | ENZYME | HORMONES | 9164869 |
Page: 1 |